Fujitsu Laboratories and Aichi Cancer Center in Japan Sign Comprehensive Joint Research Agreement to Drive Advances in Cancer Genomic Medicine with AI Technology

Utilizing AI technology to simplify details analysis and contribute to development in an emergent, yet crucial frontier of medical science

Fujitsu Laboratories Ltd. and Aichi Cancer Center(1) have actually effectively concluded a comprehensive cooperative research agreement to utilize recently established AI technology to enhance the performance of cancer genome details analysis and contribute to advances in the field of cancer genomic medicine(2).

The joint research, which develops on Fujitsu Laboratories’ current collective efforts with the Institute of Medical Science at the University of Tokyo and AI innovations cultivated by Fujitsu Laboratories(3), will make use of understanding and concerns determined through the research and scientific research studies of cancer genome healthcare at Aichi Cancer Center, in addition to massive genomic information and medical records held by the Center.

Ultimately, the outcomes of the joint research by Aichi Cancer Center and Fujitsu will lead to the advancement of different AI innovations that provide the capacity to innovate cancer genome healthcare at Aichi Cancer Center and associated medical organizations.

Background and Details of the Joint Research

The Aichi Cancer Center in Japan goals to develop a system that connects the outcomes of multigene panel screening for cancer(4) to future, advanced healthcare for cancer clients.

In the emerging field of genomic cancer medicine, a board of molecular growth professionals translates the outcomes of a client’s cancer gene profile to develop proper treatment strategies based upon their distinct situations. This procedure stays very time consuming, nevertheless, showing a difficulty for the Aichi Cancer Center and other organizations engaged in this field-as the variety of hereditary tests boosts, the problem on medical professionals, who should translate outcomes on a specific basis, continues to install.

To resolve this obstacle, Fujitsu Laboratories and Aichi Cancer Center plan to produce a brand-new AI technology to enhance the practicality of cancer genomic medicine, making use of technology at first established by Fujitsu Laboratories in a joint research job with the Institute of Medical Science at the University of Tokyo.

The brand-new technology will be established utilizing aggregated information for genomic and scientific profiles primarily for strong cancers held in trust by the Aichi Cancer Center, with the primary function of enhancing the performance of analyzing the outcomes of comprehensive genomic analyses. The job will concentrate on enhancing functions that can clarify the relationship in between genomic profiles in cancers and their responsiveness to anti-cancer reagents for cancer treatments. The objective of the effort is to eventually broaden the scope of cancers that can be targeted by genomic medicine and to provide treatments enhanced for each client.

Roles in the Joint Research Collaboration

Fujitsu Laboratories

Advancement of standard technological aspects required for database building and construction and combination of scientific details and genomic profiles for each illness location utilizing AI technology.Advancement of brand-new innovations to assistance medical diagnosis and the choice of healing reagents in cancer genomic medicine and understanding discovery for developing unique algorithms for treatments.

Aichi Cancer Center

Arrangement of patient-specific cancer genomic profiles and medical records with factor to consider for the defense of individual details.Offering information on how to translate, examine, and choose treatments for different kinds of cancer, consisting of strong tumors.Verification of the recently established AI technology in a medical setting.

Future Plans

Fujitsu Laboratories and the Aichi Cancer Center will incorporate the outcomes of the joint research into a series of functions that supports cancer genomic medicine together with AI technology established to date, and use these to healthcare facilities in the Tokai area. In addition, cancer genome information for different cases gathered from clients at healthcare facilities will be signed up in a typical recommendation database, which will be continually broadened to establish incorporated functions that make it possible for more comprehensive and dependable choice of anti-cancer drugs. This joint research effort will permit the 2 organizations to make a considerable contribution to the improvement of cancer genomic medicine in Japan.

[1] Aichi Cancer Center Designated by the Minister of Health, Labour and Welfare as a center medical facility for cancer genome healthcare.[2] Cancer Genomic Medicine A kind of treatment for cancer based upon genomic alterations/profiles, which provides physician more efficient treatment strategies utilizing of healing drugs picked based upon genomic variants/profiles to provide “precision medicine,” customized to private clients[3] The joint research, which develops on Fujitsu’s current collective efforts with the Institute of Medical Science at the University of Tokyo and AI innovations cultivated by Fujitsu Laboratories In a joint research job with the Institute of Medical Science at the University of Tokyo, Fujitsu Laboratories Ltd. has actually established AI technology that makes the evaluation of treatment policies for severe myeloid leukemia more effective and accurate. The job makes use of a database established by Fujitsu Limited in cooperation with the Japan Agency for Medical Research and Development as part of the “Program for an Integrated Database of Clinical and Genomic Information.” Details in the following news release:[4] Multigene Panel Testing for Cancer Multigene panel screening is changing scientific management of clients with cancer. The Japanese federal government authorized repayment of 2 cancer genome profiling systems under universal health protection in June 2019. These screening systems assure to play an essential function in the growth of the emerging field of cancer genomic medicine.

About Fujitsu

Fujitsu is the leading Japanese details and interaction technology (ICT) business, using a complete variety of technology items, options, and services. Around 132,000 Fujitsu individuals support consumers in more than 100 nations. We utilize our experience and the power of ICT to shape the future of society with our consumers. Fujitsu Limited (Code: 6702) reported combined incomes of 4.0 trillion yen (United States $36 billion) for the ended March 31, 2019. To find out more, please see

About Fujitsu Laboratories

Founded in 1968 as a completely owned subsidiary of Fujitsu Limited, Fujitsu Laboratories Ltd. is among the leading proving ground in the world. With an international network of laboratories in Japan, China, the United States and Europe, the company performs a large range of standard and used research in the locations of Next-generation Services, Computer Servers, Networks, Electronic Devices and Advanced Materials. To find out more, please see:

About Aichi Cancer Center

Aichi Caner Center is among the biggest and earliest comprehensive cancer centers in Japan. For more than 50 years, the Aichi Cancer Center has actually been a leader in cancer research and treatment, using state-of-the art care readily available and advancing the understanding for future enhancement. Our devoted scientific and research personnel, who are working passionately and collaboratively, are non-stop dedicated to supplying hope to presently uncurable clients and making cancer an illness of the past. To find out more, please see:

Source : Fujitsu Laboratories Ltd.

Recommended For You

About the Author: livescience

Leave a Reply

Your email address will not be published. Required fields are marked *